Fusion between tmprss2 and ets family members (ERG, ETV1, ETV4) in prostate cancers from northern china

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 4935-4938

  Wang, Jian Jiang ^a   Liu, Yue Xin ^a   Wang, Wei ^a   Yan, Wei ^a   Zheng, Yu Peng ^a   Qiao, Lu Dong ^a   Liu, Dan ^a   Chen, Shan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Fluorescence; Gene fusion; Immunity hybrid; Prostate cancer

Indexed keywords

EID: 84874013902     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.4935     Document Type: Article

References (12)

1. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA (2009). TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther, 8, 125-30.
2. Huang L, Schauer IG, Zhang J, et al (2011). The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer. Int J Clin Exp Pathol, 4, 644-50.
3. Lee K, Chae JY, Kwak C, Ku JH, Moon KC(2010). TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology, 76, 1267-8.
4. Mao X, Yu Y,Boyd LK, et al (2010). Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res, 70, 5207-12.
5. Rubio-Briones J, Fernandez-Serra A, Calatrava A, et al (2010). Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol, 183, 2054-61.
6. Song FJ, Zhang BL, He M, et al (2010). Trend analysis of the incidence of prostate cancer in Tianjin between 1981 and 2004. Zhonghua Yi Xue Za Zhi, 90, 2811-4.
7. Sun QP, Li LY,Chen Z, et al (2010). Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J Mol Diag, 12, 718-24.
8. Sun YH (2004). Research on prostate cancer in China. Chin J Urol, 25, 77-80.
9. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I (2000). Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer, 89, 2059-67.
10. Tomlins SA, Mehra R,Rhodes DR, et al (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res, 66, 3396-400.
11. Tomlins SA, Rhodes DR,Perner S, et al (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644-8.
12. Weir HK, Thun MJ, Hankey BF, et al (2003). Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 95, 1276-99.